# Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

> **NCT00925119** · PHASE4 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 31 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Atenolol

## Key facts

- **NCT ID:** NCT00925119
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2013-06
- **Final completion:** 2014-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925119, "Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00925119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*